NCT01619644View on ClinicalTrials.gov

Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Rubinstein-Taybi Syndrome
Interventions
DRUG

sodium valproate

sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour

DRUG

Placebo

Placebo with an oral dosage of 30 mg/kg/jour

Trial Locations (1)

33076

University Hospital Bordeaux, France, Bordeaux

All Listed Sponsors
collaborator

Fondation Syndrome de Rubinstein-Taybi

UNKNOWN

lead

University Hospital, Bordeaux

OTHER

NCT01619644 - Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial | Biotech Hunter | Biotech Hunter